$AFL

AFLAC, CME, Incyte, Box, Five Below Insider Shake

Insiders sold shares in AFLAC, CME, Incyte, Box, and Five Below. Japan Post sold 55,700 AFLAC shares for $6.34M. CME director sold 500 shares for $140,055. Incyte EVP sold 23,218 shares for $2.8M. Box director sold 6,158 shares for $215,530. Five Below insiders sold 6,318 shares for $1.57M.

Original reporting
Published Sep 19, 2026, 1:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 2:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AFLAC, CME, Incyte, Box, Five Below Insider Shake — source image
Decision brief

The 30-second read

$AFLBearishLow
01

Why it matters

While each sale varies in size, the collective disclosure provides traders with fresh data on insider sentiment.

02

Market read

Primary insider sale disclosures; modest trading relevance.

03

What to watch

Recent earnings or upcoming product milestones may offset the negative perception of these sales.

Relevance 4/10Novelty 4/10Timing: today

Background

The article aggregates recent Form 4 insider sales for five publicly traded U.S. companies.

Company-level read

Ticker impact

$AFLBearishMedium confidence
Context

Japan Post sold multiple blocks of AFLAC shares totaling ~55,800 shares for over $7.3M.

Expected impact

Potential short-term pressure on AFL.

Evidence & confidence

Multiple sizable disposals by a major shareholder suggest a bearish view.

$CMENeutralLow confidence
Context

Director Elizabeth Cook sold 500 CME shares for $140,055.

Expected impact

Little to no effect on CME price.

Evidence & confidence

Small volume relative to float; likely personal rebalancing.

$INCYBearishMedium confidence
Context

EVP Pablo Cagnoni sold 23,218 Incyte shares for $2.8M.

Expected impact

May weigh on INCY in the near term.

Evidence & confidence

Executive involvement in pipeline makes the sale noteworthy.

$BOXNeutralLow confidence
Context

Director Evan‑Dana L sold 6,158 Box shares for $215,530.

Expected impact

Limited impact on BOX price.

Evidence & confidence

Sale size is small relative to market cap.

$FIVEBearishMedium confidence
Context

CAO Eric Specter sold 5,500 Five Below shares for $1.37M and Jacob Kimball Hawkins sold 818 shares for $203,583.

Expected impact

Potential short-term downside pressure on FIVE.

Evidence & confidence

High‑value sales by senior officers may hint at valuation concerns.

Market effects

Insider sales across insurance, derivatives, biotech, cloud content, and discount retail may prompt sector‑wide scrutiny.

U.S. equities may see modest pressure in the mentioned stocks.

Limited to U.S. markets; no broader macro effect.

Counterpoint

Insider sells could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • AFLAC

    Insurance provider

  • CME Group

    Derivatives exchange operator

  • Incyte

    Biopharmaceutical firm

  • Box

    Cloud content management

  • Five Below

    Discount retailer

Related articles

Med

HC Wainwright & Co. reiterates Buy rating on Incyte, $152 price target

HC Wainwright & Co. reiterated a Buy rating on Incyte (INCY) with a $152 price target, suggesting a 36.5% upside from the Oct 12 close. The firm cited strong pipeline potential, particularly for drug INCB161734, with a 69% response rate in untreated patients and projected annual sales of $700 million in the U.S. G12D pancreatic cancer market.

$SNDXHighAI 8/10

Syndax shares fall as lung fibrosis drug fails trial

Syndax Pharma's shares fell 17% pre-market after abandoning its IPF drug axatilimab, which failed a phase 2 trial. The drug, partnered with Incyte, is approved for cGVHD as Niktimvo. Incyte's shares also dipped slightly. Syndax reported $152M in 2025 revenue, with $115M in the first half of 2026.

$CMEMed

FanDuel Gets FCM License, Raising Questions Over CME Role in Predicts

FanDuel has received a futures commission merchant (FCM) license from the National Futures Association, allowing it more control over its U.S. prediction market business. The approval raises questions about its partnership with CME Group, which holds a 51% stake in FanDuel Predicts. CME's CEO previously stated that such a license could conflict with their agreement. FanDuel's new license does not permit it to operate its own exchange, but it may seek further approvals in the future.

$CMEMed

Baseball may get its first stats-based trading contracts Oct. 12, pending regulatory review.

CME Group plans to launch baseball futures on October 12, 2026, pending regulatory approval. The contracts will track CME FutureSports Performance Indexes, based on official league data of 30 professional baseball teams. Standard contracts will be valued at 10x the indexes, while micro contracts will be 1/10 their value. Trading will begin with the 2026 Postseason and the four clubs in the League Championship Series.